Vistagen Therapeutics, Inc. filings document regulatory and corporate events for a Nasdaq-listed late clinical-stage biopharmaceutical company. Recent Form 8-K disclosures cover clinical program updates for fasedienol in the PALISADE social anxiety disorder program, FDA-related developments for refisolone under an IND application, and Regulation FD materials such as corporate presentations.
The company’s filings also record governance and capital-structure matters, including board departures, Audit Committee composition and Nasdaq listing-rule compliance, employee retention awards under the Amended and Restated 2019 Omnibus Equity Incentive Plan, and workforce and cash-management actions tied to clinical-development priorities.
Vistagen Therapeutics, Inc. reported that its board approved a reduction of its workforce by approximately 20%. The company states this step is intended to support disciplined cash management while focusing resources on ongoing clinical studies in its PALISADE Program for fasedienol in social anxiety disorder.
Vistagen expects topline results from its PALISADE-4 Phase 3 trial in the first half of 2026 and currently anticipates its cash runway extending into 2027. Affected employees may receive cash severance and temporary healthcare coverage if they are eligible, elect coverage, and sign a separation agreement with a general release of claims. The company expects associated costs to be immaterial but notes additional costs could arise.
Vistagen Therapeutics, Inc. reported that on February 13, 2026, board member Paul Edick resigned from its Board of Directors. The company did not provide additional details about the circumstances of his resignation.
The company stated that it is actively seeking new candidates to fill the resulting vacancy on the Board, indicating its intention to maintain a full board composition.
OrbiMed Advisors LLC and OrbiMed Capital LLC report significant ownership stakes in Vistagen Therapeutics, Inc. common stock. OrbiMed Advisors reports beneficial ownership of 1,420,300 shares, or 3.6% of the class, while OrbiMed Capital reports 1,639,700 shares, or 4.2% of the class. Together, the reporting persons hold 7.8% of Vistagen’s common stock on behalf of other persons entitled to dividends or sale proceeds. Voting and investment power are exercised through a management committee of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Commodore Capital and affiliates reported a 9.9% beneficial stake in Vistagen Therapeutics, Inc. common stock on a passive Schedule 13G/A filing. As of December 31, 2025, they may be deemed to beneficially own 4,383,508 shares through Tranche 1 and Tranche 2 warrants and a pre-funded warrant, all subject to a 9.99% beneficial ownership limitation. The report attributes investment discretion to Commodore Capital LP as manager of Commodore Capital Master LP, with managing partners Robert Egen Atkinson and Michael Kramarz. The filers certify the holdings are not for changing or influencing control of Vistagen.
Great Point Partners, LLC, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl jointly report beneficial ownership of 2,055,834 shares of Vistagen Therapeutics common stock, representing 4.95% of the class as of the event date.
The stake is held entirely through warrants to purchase 2,055,834 shares, with shared voting and dispositive power and no sole power. The warrants include a 9.99% beneficial ownership cap, and the filers certify the securities are not held to change or influence control of Vistagen.
Janus Henderson Group plc filed an amended Schedule 13G reporting that it beneficially owns 0 shares of Vistagen Therapeutics, Inc. common stock, representing 0.0% of the class as of 12/31/2025. The filing shows Janus Henderson and its affiliated asset managers have no sole or shared voting or dispositive power over Vistagen shares.
The asset manager subsidiaries exercise investment discretion on behalf of various managed portfolios, which receive all dividends and sale proceeds from securities in their accounts, but none of these portfolios own more than five percent of Vistagen’s common stock. Janus Henderson certifies that any securities were held in the ordinary course of business and not to influence control of Vistagen.
Vistagen Therapeutics, Inc. is the subject of an amended Schedule 13G filing in which StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross report beneficial ownership of 616,749 shares of common stock issuable upon exercise of warrants, representing 1.5% of the class.
The percentage is calculated using 39,495,451 shares outstanding as of November 12, 2025, plus the shares underlying these warrants. The warrants are subject to a 9.9% beneficial ownership limitation, and all voting and dispositive power over the 616,749 underlying shares is reported as shared among the reporting persons.
Vistagen Therapeutics, Inc. received an updated ownership report from Nantahala Capital Management, LLC and its managing members Wilmot B. Harkey and Daniel Mack. As of December 31, 2025, they may be deemed to beneficially own 1,953,045 shares of common stock, representing 4.71% of the class.
All 1,953,045 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive power. The reporting group states the shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Vistagen.
Vistagen Therapeutics, Inc. reported a larger quarterly loss as it continues funding late-stage development of its intranasal pherine neuroscience pipeline. For the quarter ended December 31, 2025, revenue was $0.3 million, while research and development and general and administrative expenses rose to $14.2 million and $5.6 million, respectively, leading to a net loss of $18.9 million.
For the nine-month period, revenue reached $0.8 million and net loss widened to $53.4 million as the company advanced its Phase 3 PALISADE program for fasedienol in social anxiety disorder and progressed other pherine candidates. Cash, cash equivalents and marketable securities totaled $61.8 million, but management concluded there is substantial doubt about Vistagen’s ability to continue as a going concern beyond twelve months without additional financing. The company also received a Nasdaq notice for not meeting the $1.00 minimum bid price requirement.
Vistagen Therapeutics reported fiscal 2026 third quarter results showing higher spending as it advances late-stage neuroscience programs. Revenue was modest at $0.3 million, while research and development expense rose to $14.2 million from $11.3 million, and general and administrative expense increased to $5.6 million from $4.0 million. Net loss widened to $18.9 million compared with $14.1 million a year earlier.
Cash, cash equivalents, and marketable securities totaled $61.8 million as of December 31, 2025. The PALISADE-4 Phase 3 trial of fasedienol in social anxiety disorder is ongoing, with topline results from the randomized portion expected in the first half of 2026 after refinements informed by PALISADE-3, which did not meet its primary endpoint. The company is also preparing a U.S. IND filing in the first half of 2026 for refisolone (PH80) in menopausal hot flashes and has implemented cash preservation initiatives to support completing PALISADE-4 and advancing its pherine pipeline.